TG Therapeutics’ (TGTX) Buy Rating Reaffirmed at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research report report published on Thursday morning, Benzinga reports. LADENBURG THALM/SH SH currently has a $39.00 price target on the biopharmaceutical company’s stock.

A number of other brokerages have also recently commented on TGTX. StockNews.com cut TG Therapeutics from a buy rating to a hold rating in a research report on Saturday, February 24th. The Goldman Sachs Group raised their price target on TG Therapeutics from $12.00 to $13.00 and gave the stock a neutral rating in a research report on Thursday, February 29th. HC Wainwright restated a buy rating and issued a $45.00 price target on shares of TG Therapeutics in a research report on Thursday. JPMorgan Chase & Co. restated an overweight rating and issued a $25.00 price target on shares of TG Therapeutics in a research report on Thursday. Finally, B. Riley raised their price target on TG Therapeutics from $24.00 to $29.00 and gave the stock a buy rating in a research report on Monday, February 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and an average price target of $29.00.

TG Therapeutics Stock Up 1.2 %

TGTX opened at $13.99 on Thursday. TG Therapeutics has a fifty-two week low of $6.46 and a fifty-two week high of $35.67. The company has a debt-to-equity ratio of 0.62, a quick ratio of 5.18 and a current ratio of 5.92. The company has a market capitalization of $2.16 billion, a P/E ratio of 699.85 and a beta of 2.30. The stock has a fifty day moving average of $15.13 and a 200-day moving average of $13.87.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. TG Therapeutics had a return on equity of 12.89% and a net margin of 5.42%. The company had revenue of $43.97 million during the quarter, compared to the consensus estimate of $40.06 million. During the same quarter last year, the firm earned ($0.39) earnings per share. On average, equities analysts expect that TG Therapeutics will post -0.12 EPS for the current year.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Laurence N. Charney sold 22,000 shares of TG Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $15.97, for a total value of $351,340.00. Following the transaction, the director now owns 215,229 shares in the company, valued at $3,437,207.13. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 9.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Darwin Global Management Ltd. bought a new stake in shares of TG Therapeutics during the first quarter worth about $157,187,000. State Street Corp grew its holdings in shares of TG Therapeutics by 47.8% during the second quarter. State Street Corp now owns 14,235,263 shares of the biopharmaceutical company’s stock worth $60,500,000 after purchasing an additional 4,606,679 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of TG Therapeutics by 13.3% during the third quarter. Vanguard Group Inc. now owns 14,746,392 shares of the biopharmaceutical company’s stock worth $87,299,000 after purchasing an additional 1,725,560 shares during the last quarter. Holocene Advisors LP bought a new stake in shares of TG Therapeutics during the second quarter worth about $40,380,000. Finally, 683 Capital Management LLC bought a new stake in shares of TG Therapeutics during the third quarter worth about $11,286,000. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.